Showing results (271-280 of 342) with videos related to

Sort By:
Pageof 35
Cancer Immunology, Immunotherapy : CII|April 26, 2023
Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapyYusuke Inoue, Naoki Inui, Masato Karayama, et al.
Investigational New Drugs|June 10, 2016
Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancerSeiichiro Suzuki, Masato Karayama, Naoki Inui, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|June 9, 2018
Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary DiseaseHideki Yasui, Naoki Inui, Tomoyuki Fujisawa, et al.
Respirology Case Reports|April 23, 2025
Pulmonary Hyalinizing Granuloma With Favourable and Longitudinal Treatment ResponseSuguru Kojima, Noriyuki Enomoto, Keisuke Morikawa, et al.
Thorax|March 31, 2022
Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosisHyogo Naoi, Yuzo Suzuki, Kazutaka Mori, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|August 6, 2024
Obesity impairs ciliary function and mucociliary clearance in the murine airway epitheliumYuko Tanaka, Tomoyuki Fujisawa, Shusuke Yazawa, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 26, 2011
Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)Masato Kono, Yutaro Nakamura, Takafumi Suda, et al.
BMC Cancer|July 20, 2021
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trialsSenri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, et al.
Journal of Computer Assisted Tomography|September 20, 2011
Nonspecific interstitial pneumonia: prognostic significance of high-resolution computed tomography in 59 patientsHironao Hozumi, Yutaro Nakamura, Takeshi Johkoh, et al.
BMC Cancer|March 24, 2022
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysisSenri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, et al.
Pageof 35